News

Take the chance to win a two-night stay in Dubai for two people! You'll enjoy a stay

Written by David and verified by Ionis Following the recent announcement by Ionis about the clinical trial at

Charlie is one of the children taking part in the Natural Evolution Study (NHS) conducted by Ionis Pharmaceuticals in the United States. The study has

In February 2024, David Covini, President of DupMECP2, visited the biotech company HuidaGene Therapeutics in Shanghai. This visit

A revolutionary technology with high potential in MECP2 gene duplication syndrome The world of genetic engineering has

Huidagene Therapeutics is a biotechnology company based in Shanghai and New Jersey, focusing on the

On 28 October, members of our team: Ana (member of the Board of Directors), Caroline (member of the Board of Directors, Vice-President),

Exactly one year ago, the "Lasst uns MDS heilen - DupMECP2" association was founded. The history of the association

10 March 2023 marks a very important date for the rare disease community. Trofinetide has been approved